Class information for:
Level 1: DRUG INDUCED LUPUS//DRUG INDUCED LUPUS ERYTHEMATOSUS//TNF ALPHA ANTAGONISTS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
15512 638 33.2 86%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
669 12548 PSORIASIS//PSORIATIC ARTHRITIS//CALCIPOTRIOL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DRUG INDUCED LUPUS Author keyword 4 21% 3% 18
2 DRUG INDUCED LUPUS ERYTHEMATOSUS Author keyword 3 37% 1% 7
3 TNF ALPHA ANTAGONISTS Author keyword 2 15% 2% 15
4 ANTIBODIES MONOCLONAL ADVERSE EFFECTS Author keyword 2 67% 0% 2
5 DRUG INDUCED PSORIASIS Author keyword 2 67% 0% 2
6 LUPUS LIKE REACTION Author keyword 2 67% 0% 2
7 LUPUS SYNDROME Author keyword 2 67% 0% 2
8 PSORIASIFORM ERUPTION Author keyword 2 50% 0% 3
9 TUMOR NECROSIS FACTOR ALPHA ANTAGONIST Author keyword 2 26% 1% 5
10 ADALIMUMB Author keyword 1 100% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 DRUG INDUCED LUPUS 4 21% 3% 18 Search DRUG+INDUCED+LUPUS Search DRUG+INDUCED+LUPUS
2 DRUG INDUCED LUPUS ERYTHEMATOSUS 3 37% 1% 7 Search DRUG+INDUCED+LUPUS+ERYTHEMATOSUS Search DRUG+INDUCED+LUPUS+ERYTHEMATOSUS
3 TNF ALPHA ANTAGONISTS 2 15% 2% 15 Search TNF+ALPHA+ANTAGONISTS Search TNF+ALPHA+ANTAGONISTS
4 ANTIBODIES MONOCLONAL ADVERSE EFFECTS 2 67% 0% 2 Search ANTIBODIES++MONOCLONAL+ADVERSE+EFFECTS Search ANTIBODIES++MONOCLONAL+ADVERSE+EFFECTS
5 DRUG INDUCED PSORIASIS 2 67% 0% 2 Search DRUG+INDUCED+PSORIASIS Search DRUG+INDUCED+PSORIASIS
6 LUPUS LIKE REACTION 2 67% 0% 2 Search LUPUS+LIKE+REACTION Search LUPUS+LIKE+REACTION
7 LUPUS SYNDROME 2 67% 0% 2 Search LUPUS+SYNDROME Search LUPUS+SYNDROME
8 PSORIASIFORM ERUPTION 2 50% 0% 3 Search PSORIASIFORM+ERUPTION Search PSORIASIFORM+ERUPTION
9 TUMOR NECROSIS FACTOR ALPHA ANTAGONIST 2 26% 1% 5 Search TUMOR+NECROSIS+FACTOR+ALPHA+ANTAGONIST Search TUMOR+NECROSIS+FACTOR+ALPHA+ANTAGONIST
10 ADALIMUMB 1 100% 0% 2 Search ADALIMUMB Search ADALIMUMB

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NO RELAPSE 11 100% 1% 6
2 INFLIXIMAB INDUCED LUPUS 9 83% 1% 5
3 FACTOR ALPHA THERAPY 7 17% 6% 39
4 FACTOR ANTAGONIST THERAPY 7 50% 2% 10
5 NEW ONSET PSORIASIS 6 71% 1% 5
6 NEW ONSET 6 19% 5% 29
7 ANTI TNF ALPHA 6 17% 5% 31
8 ANTAGONIST THERAPY 6 33% 2% 14
9 FLEXURAL PSORIASIS 6 100% 1% 4
10 ETANERCEPT THERAPY 5 17% 4% 28

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents 2014 22 32 66%
Demyelination and other neurological adverse events after anti-TNF therapy 2014 17 40 58%
Biologics-induced autoimmune diseases 2013 34 41 49%
Drug-induced lupus due to anti-tumor necrosis factor alpha agents 2008 100 25 84%
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata - First 120 cases from the literature including a series of six new patients 2008 126 29 59%
Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: A systematic literature review based on 222 cases 2013 15 44 70%
Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis 2010 61 59 66%
TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists 2011 37 29 69%
Paradoxical inflammation induced by anti-TNF agents in patients with IBD 2012 38 82 39%
Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety 2015 2 127 19%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 AUTOIMMUNE DIS JOSEP FONT AUTOIMMUNE DIS 1 33% 0.3% 2
2 UNIT 02 UR 09 01 1 33% 0.3% 2
3 CATTEDRA UOC REUMATOL 1 50% 0.2% 1
4 DIPARTIMENTO MED SISTEMI DERMATOL 1 50% 0.2% 1
5 EQUIPE AVENIR MALAD PRIONS CHEZ HOMME 1 50% 0.2% 1
6 FDN HOSP LA FE 1 50% 0.2% 1
7 GASTROENTEROL MED INFLAMMATORY BOWEL 1 50% 0.2% 1
8 HAMATOONKOL 1 50% 0.2% 1
9 HOSP TERR 1 50% 0.2% 1
10 MINJOZ TEACHING HOSP 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000158073 PHARMACEUT PROTE//PRE LIGAND BINDING ASSEMBLY DOMAIN PLAD//TUMOR NECROSIS FACTOR RECEPTOR TNFR
2 0.0000155997 INFLIXIMAB//VEDOLIZUMAB//ADALIMUMAB
3 0.0000145111 PSORIASIS//EFALIZUMAB//ALEFACEPT
4 0.0000133151 ABATACEPT//TOCILIZUMAB//DISEASE MODIFYING ANTIRHEUMATIC DRUGS
5 0.0000119637 RHEUMATOID VASCULITIS//RHEUMATOID MYOSITIS//EXTRAARTICULAR MANIFESTATIONS
6 0.0000103498 PROPYLTHIOURACIL//BENZYLTHIOURACIL//DRUG INDUCED LUPUS
7 0.0000078699 IL10 GENE//INTERLEUKIN 10 PROMOTER//RHEUMATOL INTERNAL MED 3
8 0.0000071270 ANTI TNF ALPHA THERAPIES//GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID//PATHOL RHEUMATOL
9 0.0000062574 BIOCHEM BIOTECH DRUGS//CEREBROVASCULAR THROMBOSIS//EXTRAINTESTINAL COMPLICATION
10 0.0000061255 IMMUNODEFICIENCY ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS//RADIATION THERAPY COMPLICATIONS//STANDARDIZED INCIDENCE RATE